Previous close | 3.6400 |
Open | 3.6900 |
Bid | 3.7000 x 100 |
Ask | 3.7700 x 100 |
Day's range | 3.6000 - 3.7400 |
52-week range | 2.2150 - 10.1400 |
Volume | |
Avg. volume | 1,322,625 |
Market cap | 834.418M |
Beta (5Y monthly) | 2.64 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.3200 |
Earnings date | 15 Aug 2024 - 19 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.39 |
CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Key Insights The projected fair value for CureVac is US$5.84 based on 2 Stage Free Cash Flow to Equity CureVac is...
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.